Literature DB >> 2136835

Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects.

J A Marcondes1, B L Wajchenberg, A C Abujamra, W W Luthold, E Samojlik, M A Kirschner.   

Abstract

Cyproterone acetate given as a single intramuscular dose of 300 mg monthly for 6 months resulted in significant reduction of hirsutism without appreciable side effects. This regimen resulted in decreased levels of luteinizing hormone (LH) and estradiol in the eight women studied. No significant changes were observed in total serum testosterone (T) levels, however, there was a reduction in sex hormone binding globulin (SHBG), resulting in lowered SHBG-bound T, and an increase in non-SHBG-T over this time. Serum androstanediol glucuronide levels decreased in three of four women, although not to normal levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2136835     DOI: 10.1016/s0015-0282(16)53213-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.

Authors:  J A Marcondes; S L Minanni; W W Luthold; A C Lerário; M Nery; B B Mendonça; B L Wajchenberg; M A Kirschner
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

Review 2.  Cyproterone acetate for hirsutism.

Authors:  Z M Van der Spuy; P A le Roux
Journal:  Cochrane Database Syst Rev       Date:  2003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.